Affiliations 

  • 1 Department of Pharmaceutics, JSS College of Pharmacy, JSS Academy of Higher Education and Research, Mysuru, 570015 Karnataka, India
  • 2 Department of Pharmaceutical and Environmental Health Sciences, College of Pharmacy and Health Sciences, Texas Southern University, 3100 Cleburne Street, Houston, Texas 77004, United States
  • 3 Department of Pharmaceutics, Krishna Institute of Pharmacy, Krishna Institute of Medical Sciences, Deemed to be University, Karad 415539, Maharashtra, India
  • 4 Pharmacology Unit, Faculty of Pharmacy, AIMST University, Semeling, Bedong, 08100 Kedah Darul Aman, Malaysia
  • 5 Department of Pharmacy Practice, JSS College of Pharmacy, JSS Academy of Higher Education and Research, Mysuru, 570015 Karnataka, India
ACS Chem Neurosci, 2020 10 07;11(19):2962-2977.
PMID: 32945654 DOI: 10.1021/acschemneuro.0c00555

Abstract

Glioblastoma multiforme (GBM), a standout among the most dangerous class of central nervous system (CNS) cancer, is most common and is an aggressive malignant brain tumor in adults. In spite of developments in modality therapy, it remains mostly incurable. Consequently, the need for novel systems, strategies, or therapeutic approaches for enhancing the assortment of active agents meant for GBM becomes an important criterion. Currently, cancer research focuses mainly on improving the treatment of GBM via diverse novel drug delivery systems. The treatment options at diagnosis are multimodal and include radiation therapy. Moreover, significant advances in understanding the molecular pathology of GBM and associated cell signaling pathways have opened opportunities for new therapies. Innovative treatment such as immunotherapy also gives hope for enhanced survival. The objective of this work was to collect and report the recent research findings to manage GBM. The present review includes existing novel drug delivery systems and therapies intended for managing GBM. Reported novel drug delivery systems and diverse therapies seem to be precise, secure, and relatively effective, which could lead to a new track for the obliteration of GBM.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.